The rationale for targeting mucins rests on their central role in tick biology. Mucins are heavily glycosylated proteins that, in ticks, contribute to the formation of the cement cone that anchors the mouthparts into the host skin during feeding, help modulate the host immune response at the bite site, and participate in assembling the peritrophic membrane that lines the tick gut and protects it from ingested blood and microbes. Because these functions are essential to feeding and survival, proteins involved in them are attractive vulnerabilities: antibodies circulating in the host’s blood would be ingested by the tick and could interfere with these processes from within the parasite.

Before committing to laboratory production, the team characterized Mucin-6 using bioinformatic tools. The predictions indicated a hydrophilic but intrinsically unstable protein with a molecular mass of 24.9 kilodaltons after removal of its signal peptide, the short N-terminal sequence that normally directs secretion. Importantly for vaccine design, the sequence was predicted to be rich in linear B-cell epitopes, the short stretches of amino acids that antibodies can recognize on a denatured or soluble protein. Abundant epitopes increase the likelihood that vaccination will elicit a robust and specific humoral response, which is the arm of immunity most relevant for an antigen that will be encountered by the tick through a blood meal.

To confirm that the gene is biologically relevant throughout the tick life cycle, the researchers used quantitative PCR to measure Mucin-6 expression across developmental stages and feeding states. The gene was transcribed at every stage examined, from larva to adult, with significantly higher expression in eggs. This broad and consistent expression profile matters for vaccine utility: an antigen expressed only in a narrow stage or feeding condition would leave windows in which the parasite is unprotected, whereas a constitutively expressed protein offers a target throughout the tick’s interaction with the vaccinated host.

With the sequence validated, the team moved to recombinant production. The Mucin-6 coding sequence was cloned into the pET28a expression vector and transformed into BL21(DE3) Escherichia coli, a standard laboratory strain engineered for high-level protein expression under T7 promoter control. On induction, the recombinant protein accumulated in inclusion bodies, the dense aggregates of misfolded protein that bacteria often form when expressing foreign or disulfide-rich proteins. The researchers recovered the protein from these bodies, renatured it to restore a soluble conformation, and purified it using nickel-nitrilotriacetic acid affinity chromatography, which exploits the histidine tag encoded by the pET28a vector. On SDS-PAGE, the purified recombinant Mucin-6 migrated at approximately 41 kilodaltons, larger than the predicted 24.9 kilodaltons of the mature protein, a discrepancy consistent with the tag and the anomalous electrophoretic behavior typical of mucin-like, compositionally biased proteins.

The immunization trial used six New Zealand White rabbits randomly assigned to a vaccinated group of three and a phosphate-buffered saline control group of three. Each vaccinated rabbit received 500 micrograms of recombinant Mucin-6 formulated with Freund’s adjuvant in three subcutaneous injections spaced 14 days apart. Enzyme-linked immunosorbent assays tracked the antibody response, revealing titers that reached 1:512,000 by day 35, an exceptionally high level indicating strong recognition of the recombinant antigen. Fourteen days after the final booster, the researchers challenged each rabbit with 30 adult ticks, 15 males and 15 females, and measured the parameters that define tick vaccine efficacy: engorgement weight, egg mass, blood-feeding duration and egg-hatching rate.

The results showed a consistent, statistically significant burden on the parasites. Ticks that fed on immunized rabbits had engorged body weights reduced by 13.6 percent and egg masses reduced by 14.7 percent compared with ticks fed on control rabbits, both differences significant at P less than 0.05. Blood-feeding duration was prolonged by 8.3 percent, suggesting that antibodies disrupted the efficiency of feeding, forcing ticks to remain attached longer to obtain a full blood meal. Combining the effects on tick weight and fecundity, the authors calculated an overall vaccine efficacy of 26.3 percent. While modest compared with the best commercial anti-tick formulations, this figure represents a meaningful proof of concept for a single antigen tested in its first host species.

A critical question for any recombinant antigen is whether antibodies raised against the laboratory-produced protein also recognize the native version in the parasite. The team addressed this by western blot, incubating tick lysates with serum from the immunized rabbits. The anti-rMucin-6 serum bound native Mucin-6 in tick extracts, confirming that the recombinant protein preserved epitopes present in the authentic tick protein and that the antibodies generated in the vaccinated animals could, in principle, engage their target during a natural blood meal. This cross-recognition underpins the observed phenotypic effects and strengthens the case that Mucin-6, rather than an artifact of immunization, is the operative antigen.

The study sits within a broader effort to develop anti-tick vaccines that reduce both parasite loads and pathogen transmission without the drawbacks of chemical acaricides. The only commercially available tick vaccine, based on the gut antigen Bm86 against Rhipicephalus microplus, demonstrated decades ago that vaccinating the host can starve and sterilize ticks from within, but its efficacy varies across tick species and regions, driving the search for new antigens. Secreted proteins such as mucins, which are exposed to host antibodies in the ingested blood and are functionally indispensable, form a promising class of candidates. The Hainan team’s work adds Mucin-6 to this pipeline and demonstrates a complete workflow, from epitope prediction and expression profiling through prokaryotic production and a controlled animal challenge.

Limitations remain before Mucin-6 could approach practical deployment. The trial involved a small number of animals, a single antigen and a single host species, and Freund’s adjuvant is unsuitable for veterinary or human use, so future work would need to test the antigen with licensed adjuvants, in larger cohorts, and ideally in combination with other antigens to push efficacy higher. The authors, led by corresponding author Qingfeng Guan with co-first authors Jie Chen and Yongchuan Zhu, conclude that Mucin-6 merits further evaluation as a candidate vaccine antigen against R. linnaei. Given that tick-borne diseases continue to expand their geographic range with changing climates and livestock movements, even incremental gains from antigen discovery of this kind carry substantial implications for animal health and the economics of tick control.

Subject of Research: Evaluation of the tick protein Mucin-6 from Rhipicephalus linnaei as a recombinant anti-tick vaccine antigen

Article Title: Prokaryotic expression and vaccine potential of Mucin-6 from Rhipicephalus linnaei

Article References: Chen, J., Zhu, Y., Zhao, J., Wang, J., Han, Q., & Guan, Q. (2026). Prokaryotic expression and vaccine potential of Mucin-6 from Rhipicephalus linnaei. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07675-9

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07675-9

Keywords: Rhipicephalus linnaei, Mucin-6, anti-tick vaccine, recombinant protein, prokaryotic expression, vaccine efficacy, tick control, humoral immunity, B-cell epitopes, Parasites & Vectors, livestock health, vector biology

Toxoplasma gondii infects an estimated third of the human population, usually without symptoms, but it can cause severe disease in immunocompromised people and in fetuses when a woman acquires the parasite for the first time during pregnancy. The parasite’s life cycle depends on cats: after a cat eats tissue cysts in infected prey, the parasite reproduces sexually in the cat’s intestine and millions of resistant oocysts are shed in feces, contaminating soil, water, and food. Identifying which cats carry the parasite therefore sits at the hinge of prevention strategies. Yet existing serological tests for feline toxoplasmosis face a trade-off. Whole-parasite lysate antigens deliver sensitivity but are expensive and laborious to produce, requiring the propagation of live parasites, while single recombinant antigens are convenient but can miss infections because antibody responses vary between animals and across stages of infection.

The research team, led by scientists at Tarim University in Xinjiang and the Shanghai Veterinary Research Institute of the Chinese Academy of Agricultural Sciences, set out to combine the breadth of whole-parasite antigens with the convenience and consistency of recombinant proteins. Their strategy began with the rational selection of six T. gondii antigens that are well characterized in the literature: SAG1 and SAG2, surface proteins abundantly displayed on tachyzoites; ROP1, a component of the rhoptry organelles the parasite uses to invade host cells; GRA1, a dense granule protein involved in modifying the vacuole the parasite occupies inside cells; and two further candidates, LEA870 and LEA880. Each of these antigens is known to be recognized by antibodies during natural infection, making their epitopes logical building blocks for a synthetic diagnostic target.

Once the antigens were chosen, the team turned to bioinformatics to identify the dominant B-cell epitopes within them, the short linear stretches of amino acids most likely to be exposed on the protein surface and most likely to be bound by antibodies circulating in infected cats. Epitope prediction tools evaluate properties such as hydrophilicity, surface accessibility, flexibility, and sequence conservation to score each region. The strongest candidate peptides from all six antigens were then linked in tandem into a single open reading frame and cloned for expression, producing one recombinant fusion protein the authors named Polyantigenic Epitope Peptide 1, or PEP1. The logic is straightforward: by fusing epitopes from multiple antigens into one molecule, the assay gains multiple opportunities to capture antibodies from a serum sample, whatever the individual animal’s antigen preference or infection stage might be.

With PEP1 in hand, the researchers optimized every step of the indirect ELISA protocol. Using checkerboard titration, a method in which antigen concentrations and serum dilutions are varied simultaneously in a matrix, they identified the conditions that maximize the signal difference between positive and negative sera. The final recipe calls for coating microplate wells with PEP1 at 5 micrograms per milliliter overnight at 4 degrees Celsius for 12 hours, then blocking residual binding sites with 0.5 percent bovine serum albumin for 60 minutes at 37 degrees Celsius. Test sera are diluted 1:1,000 and incubated for 45 minutes, followed by an enzyme-conjugated secondary antibody diluted 1:2,500 for an hour. The colorimetric reaction is developed with the chromogenic substrate 3,3′,5,5′-tetramethylbenzidine, TMB, for 25 minutes at room temperature in the dark before the optical density is read. Each parameter was validated after the titration, ensuring the protocol is reproducible rather than a lucky configuration.

The performance figures reported for the assay are the heart of the study. In preliminary evaluation, PEP1-based iELISA showed no cross-reactivity with serum samples positive for three clinically important feline viruses: feline panleukopenia virus, feline herpesvirus, and feline calicivirus. Cross-reactivity is the perennial weakness of serology, since antibodies to unrelated pathogens can sometimes bind assay antigens and generate false positives; the absence of such reactions here speaks to the specificity of the chosen epitopes. The detection limit of the assay extended to a serum dilution of 1:6,400, meaning that even antibodies present at very low concentration in highly diluted samples were still detected, an indication of high analytical sensitivity. Reproducibility was assessed by repeating the assay within a single plate and across separate plates on different days; both the intra-assay and inter-assay coefficients of variation remained below 10 percent, a conventional benchmark for a robust immunoassay.

Perhaps most convincing is how the new assay fared against an established comparator. The researchers ran the PEP1 assay in parallel with an iELISA based on T. gondii lysate antigen, TLA-iELISA, on 78 feline serum samples. The two methods agreed on 97 percent of samples, suggesting that the artificial multi-epitope protein performs on par with an antigen preparation drawn from whole parasites. That is a meaningful result because TLA is widely regarded as a sensitive coating antigen but carries practical drawbacks: it must be prepared from parasite cultures, varies between batches, and raises biosafety and cost considerations. A single recombinant protein produced in bacteria, by contrast, can be manufactured in large, consistent quantities, lyophilized for stability, and shared between laboratories with minimal variation, making large-scale screening of cat populations far more feasible.

The authors frame the work not only as a diagnostic advance but as a platform for future research. A reliable serological test is a prerequisite for evaluating vaccine efficacy in cats, because any trial of a feline toxoplasmosis vaccine must distinguish vaccinated-and-protected animals from naturally infected ones, and must track antibody responses over time. The paper’s conclusions state that the PEP1-based indirect ELISA is a reliable tool for the serodiagnosis of feline toxoplasmosis and provides a solid technical platform for future studies of vaccine efficacy. Given that several candidate vaccines against T. gondii in cats have been explored without one reaching broad deployment, having a standardized, reproducible serological readout could accelerate that pipeline considerably.

The broader implications extend to public health, where cats occupy a unique and paradoxical position: beloved companions in tens of millions of households, yet the definitive host of a parasite that causes congenital infection worldwide. Routine, affordable screening could inform advice to pregnant women and immunocompromised individuals about the risk posed by their pets, guide removal of infected animals from catteries and shelters, and support surveillance in regions where the parasite is endemic. The study’s technical approach, epitope prediction followed by gene synthesis of a poly-epitope fusion protein, is also a template that could be adapted to other pathogens where multi-antigen coverage is desirable but whole-organism antigens are impractical. In that sense, the contribution is as much methodological as it is pathogen-specific.

The work was supported by the National Natural Science Foundation of China and the National Key Research and Development Program of China, and was conducted with approval from the Animal Administration and Ethics Committee of the Shanghai Veterinary Research Institute. Positive feline serum samples were generously provided by Professors Chunchun Meng and Quan Wang of the Shanghai Veterinary Research Institute, while clinically derived samples came from collaborating veterinary hospitals in Shanxi and Henan provinces. As the world continues to grapple with a parasite that infects humans and animals across every continent, a simple engineered protein that captures the antibody signature of infection in the parasite’s definitive host is a small molecule with an outsized role to play.

Subject of Research: Development of a recombinant multi-epitope protein-based serological assay for detecting Toxoplasma gondii antibodies in cats

Article Title: Development of a serological assay based on a recombinant protein containing polyantigenic epitope peptides derived from Toxoplasma gondii

Article References: Sun, L., Feng, W., Cao, J., Zhou, Y., Zhou, J., Wu, J., & Zhang, H. (2026). Development of a serological assay based on a recombinant protein containing polyantigenic epitope peptides derived from Toxoplasma gondii. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07686-6

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07686-6

Keywords: Toxoplasma gondii, feline toxoplasmosis, serological assay, ELISA, recombinant protein, polyantigenic epitope peptides, SAG1, B-cell epitopes, diagnostics, parasitology, cats, public health